UNASSIGNED: 7237 Background: The purpose of this study was to determine maximum tolerated dose (MTD) and the dose-limiting @entity137 (DLT) of a combination of @entity136 plus @entity3003 administration in a biweekly schedule for inoperable @entity1149 . METHODS: @entity1 with inoperable stages IIIB and IV @entity1149 included in this study were treated with @entity3003 followed by @entity136 . @entity3003 was given intravenously over 30 minutes, and @entity136 was given intravenously over 30 minutes. RESULTS: Fifteen @entity1 were treated at 4 dose levels. As DLT, treatment delay occurred at dose level 4 in 2 of the 6 @entity1 . No DLT was experienced in dose levels 1, 2, and 3. No other grade 3/4 @entity137 was observed. Twelve @entity1 were available for evaluation of efficacy. Four @entity1 achieved partial response. CONCLUSIONS: MTD was not reached in this study. Considering the treatment continuation, the recommended dose for phase II study is @entity3003 AUC 3 and @entity136 1000mg/m(2) administration every 2 weeks. [Figure: see text] No significant financial relationships to disclose.

A phase I study of biweekly combination chemotherapy with @entity136 (GEM) and @entity3003 ( @entity3003 ) for inoperable stages IIIB and @entity1149 ( XXXX ).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity1149 :: (MESH:D002289,Disease) :: ['NSCLC']
